Leonardo J. Solmesky, Ph.D. Email and Phone Number

Planning, design, integration, maintenance, repair, programming, and operation of automated drug discovery platforms in the drug discovery unit of the Israel National Center for Personalized Medicine (G-INCPM). Leading projects of drug discovery. Scouting to bring new customers to the unit. Working with service providers. Supervision and training assistants. Teaching at drug discovery course. Established in 2012 by the Weizmann Institute of Science, the Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM) is an advanced research facility that strives to promote the field of personalized medicine by providing Israeli academic, medical, and biomedical industry researchers with access to state-of-the-art genomics, protein profiling, drug discovery and bioinformatics research platforms and know-how.

Consultant for automation issues in the company.Centarix was founded with the purpose of developing longevity-technologies to extend human health span and maximize quality of life.Aging is the ultimate challenge for modern medicine. The aging process has a devastating effect on human life quality, and eventually leads to the onset of age-related diseases which are the main killers in developed countries. In recent years, major breakthroughs in the science of aging have shown that it is possible to intervene in multiple ways with the aging process to slow it down and even reverse some of its aspects. Such interventions were shown to significantly increase healthspan and lifespan in animal models.In order to evaluate the success of potential interventions for the aging process in reasonable time frames, good biomarkers of aging are needed in order to accurately and reliably measure biological age. Such biomarkers have been shown to predict mortality and morbidity. At Centarix we are developing the ability to evaluate a wide panel of molecular and cellular biomarkers of aging, and new technologies to increase the accuracy and lower the cost of measuring biomarkers of aging.

Member of the committee for evaluation of research proposals (Argentina-Israel bilateral cooperation)

Current Research in Drug Discovery is a peer-reviewed open access journal that publishes original research papers and review articles on drug discovery and development. Focused on small molecules, specific areas of interest include: screening technologies, target and lead identification and validation, laboratory automation, high throughput screening, assay development and validation, high content analysis, data mining, biomarkers discovery, ADME, BioMEMS, microfluidics, sample management, biobanking, cell based assay, 3D cell culture, and phenotypic screening. We strongly encourage young researchers to submit their original works. Website: http://thescipub.com/crdd.toc

Consultant for automation issues in the company.

Cell-based assay development & screening for drug discovery projects for the company & global pharma partners. Preclinical development of a stem cell based product for a neurodegenerative disease (currently in clinical phase). Supervision & training of assistants. Automation of the lab.

Leading projects of drug discovery & nanotechnology for academia & pharma. Discovery of a drug candidate that it is currently showing good results in a rare disease's clinical trial. Training/supervision of students/postdoc/staff. See more information on: https://en-lifesci.tau.ac.il/drug_discovery or at https://www.facebook.com/CSFPM

ALS biomarker discovery with parallel training at Harvard on drug discovery, imaging & automation.

Quality assurance, research and development of pharmaceuticals.

Department of Medical Communications